Recent studies have centered on the convergence of GLP-1|GIP|GCGR activator therapies and dopamine signaling. While GLP activators are commonly employed for managing type 2 T2DM, their unexpected effects on reward circuits, specifically influenced by dopaminergic pathways, are gaining significant interest. This article presents a summary overvie… Read More